6 results
The objectives of this open-label study are to evaluate the efficacy (GL-3 clearance), pharmacokinetics (PK), and safety parameters (including immunogenicity) for 2 alternative dose regimens of Fabrazyme (0.5 mg/kg every 2 weeks [q2w] and 1.0 mg/kg…
Measuring the forces exerted on upper en lower teeth during classic (direct) and (indirect) (video)laryngoscopy.
Measuring the space on the right side of the videolaryngoscope blade and the palatopharyngeal wall in a cohort of ASA I-III patients with a normal mouth opening (Mallampati I, II and III). We also want to investigate how this space differs from the…
We want to determine if epiglottic downfolding leads to a better view of the glottis and more successful intubations. We also want to investigate if this comes at the cost of more postoperative sore throat, dysphonia, dysphagia and coughing…
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.